The role of PARP in the DNA damage response has been studied extensively, and its inhibition is widely used in breast and ovarian cancer with BRCA1/BRCA2 mutations [150,151,152]; PARP inhibitors mainly target defective homologous recombination [153]. The gene discussed is PARP1; the disease is ovarian carcinoma.